Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study

Oral, Aydan; Lorenc, R

doi:10.3944/aott.2015.14.0082

Cited by 8 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ninety-five percent of patients came from two studies [ 24 , 35 ]. The majority of patients were female, and eight studies included solely females [ 22 , 25 – 28 , 30 , 32 ]. Seven studies were European [ 22 , 26 , 27 , 30 – 33 ], five studies North-American [ 24 , 25 , 29 , 34 , 35 ], two from Australia [ 21 , 28 ], and one from Japan [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

“…Follow-up time varied from 6 to 24 months [ 21 , 28 ]. Interventions were executed in secondary care ( n = 13) [ 22 – 32 , 34 , 35 ], primary care ( n = 1) [ 33 ], or in both primary and secondary care ( n = 1) [ 21 ]. Seven of the 15 interventions were conducted by either physicians and/or nurses/nurse practitioners ( n = 7) [ 21 , 24 , 26 – 28 , 31 , 34 ].…”

Section: Resultsmentioning

confidence: 99%

“…Other interventions were conducted by trained coordinators ( n = 1) [ 35 ], medical secretaries ( n = 1) [ 22 ], pharmacists ( n = 1) [ 33 ], or a combination of physicians and allied healthcare workers ( n = 1) [ 36 ]. Four studies did not report by whom the intervention was conducted [ 23 , 25 , 30 , 32 ].…”

Section: Resultsmentioning

confidence: 99%

“…Implementation was described as medication possession rate (MPR) ≥ 80% [ 21 , 22 , 28 , 33 , 35 ], a medication possession rate (MPR) ≥ 50% [ 32 , 35 ], per the instructions of the physician at regular intervals and dosages [ 30 ], the percentage of the prescribed dose taken [ 27 ], scoring ≥ 75% on the Morisky Medication Adherence Scale (MMAS) [ 31 ], self-report of current osteoporosis medication use at 6 months [ 25 ], or active treatment 12 months after initiation [ 34 ]. Discontinuation was described as continuing to receive treatment over the long term [ 30 ], as permanently stopping anti-osteoporosis medication [ 33 ], continuation of treatment after 26 weeks [ 32 ], or continuing of medication after 1 year [ 22 ]. Persistence was mentioned as an outcome in three studies [ 26 , 27 , 31 ].…”

Section: Resultsmentioning

confidence: 99%

“…Three studies evaluated the effect of alterations in drug regimen compared with usual care. Of these studies, two were RCTs and one was an observational study [ 23 , 32 , 33 ]. Adherence (not further defined) was the primary outcome in one study [ 23 ], while the two other studies focused on both implementation and discontinuation [ 32 , 33 ].…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review

et al. 2020

View full text Add to dashboard Cite

Summary An earlier systematic review on interventions to improve adherence and persistence was updated. Fifteen studies investigating the effectiveness of patient education, drug regimen, monitoring and supervision, and interdisciplinary collaboration as a single or multi-component intervention were appraised. Multicomponent interventions with active patient involvement were more effective. Introduction This study was conducted to update a systematic literature review on interventions to improve adherence to anti-osteoporosis medications. Methods A systematic literature review was carried out in Medline (using PubMed), Embase (using Ovid), Cochrane Library, Current Controlled Trials, ClinicalTrials.gov , NHS Centre for Review and Dissemination, CINHAL, and PsycINFO to search for original studies that assessed interventions to improve adherence (comprising initiation, implementation, and discontinuation) and persistence to anti-osteoporosis medications among patients with osteoporosis, published between July 2012 and December 2018. Quality of included studies was assessed. Results Of 585 studies initially identified, 15 studies fulfilled the inclusion criteria of which 12 were randomized controlled trials. Interventions were classified as (1) patient education ( n = 9), (2) drug regimen ( n = 3), (3) monitoring and supervision ( n = 2), and (4) interdisciplinary collaboration ( n = 1). In most subtypes of interventions, mixed results on adherence (and persistence) were found. Multicomponent interventions based on patient education and counseling were the most effective interventions when aiming to increase adherence and/or persistence to osteoporosis medications. Conclusion This updated review suggests that patient education, monitoring and supervision, change in drug regimen, and interdisciplinary collaboration have mixed results on medication adherence and persistence, with more positive effects for multicomponent interventions with active patient involvement. Compared with the previous review, a shift towards more patient involvement, counseling and shared decision-making, was seen, suggesting that individualized solutions, based on collaboration between the patient and the healthcare provider, are needed to improve adherence and persistence to osteoporosis medications.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

Wells

Hsieh

Zheng

et al. 2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Current situation of shared decision making in osteoporosis: A comprehensive literature review of patient decision aids and decision drivers

Nogués

Carbonell

Canals

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aims Osteoporosis is a systemic skeletal disease characterized by low bone mass and microstructural deterioration of bone tissues, resulting in bone fragility and increased fracture risk. It is the most common bone‐related disease in the population. However, the proportion of patients who start treatment but discontinue it during the first year is very high (around 50%). Endeavors are made to promote patient participation in treatment by implementing patient decision aids (PDA), whose function is to help the patient make disease‐related decisions. We aim to summarize the characteristics of the currently available PDA for osteoporosis, as well as deciding factors. Methods Comprehensive review of the literature. Results Currently, eleven PDAs can be found for osteoporosis. These PDA have different characteristics or options such as information about treatments tailored to patient needs, graphic information of the results (to facilitate understanding), personal histories (learning), tests to check the knowledge acquired, provision of evidence, clinical practice guidelines or a final summary to share with their doctor. Only five of these PDAs can be considered complete since they provide relevant disease information and therapeutic options to the patient, promote patient's reflection and foment patient‐physician discussion. Conclusions This study provides an update on the current state of decision making on osteoporosis and available PDA, which can help engage the patient through shared decision‐making by considering, among other things, patient preferences. Physicians should consider PDA, as it may promote adherence and effectiveness of treatment.

show abstract

Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study

Abstract: A flexible dosing with daily risedronate appears be a valuable option in terms of compliance and persistence for patients with postmenopausal OP.

Cited by 8 publications

References 37 publications

Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review

Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

Current situation of shared decision making in osteoporosis: A comprehensive literature review of patient decision aids and decision drivers

Contact Info

Product

Resources

About